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WHAT THIS PAPER ADDS
 This report presents a monocentric homogeneous series of patients treated for secondary aorto-enteric ﬁstulae by in-situ recon-
struction using the same conduit material, that is, a silver-coated Dacron prosthesis. Findings show that successful treatment
depends on the quality of both vascular reconstruction and visceral repair. The latter step is a determinant for postoperative
mortality and recurrence of graft infection.a r t i c l e i n f o
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Objectives: The purpose of this study was to assess short- and mid-term results of in-situ revascular-
isation (ISR) using silver-coated Dacron prostheses and bowel repair for management of secondary aorto-
enteric ﬁstulae (SAEF).
Design: Single-centre retrospective chart review.
Material and methods: This study includes all the patients treated by ISR using silver-coated Dacron for
SAEF between 2006 and 2010. Primary end points were mortality and survival rates. Secondary end
points were reinfection-free survival and secondary patency rates.
Results: Eighteen male patients with SAEF with a median age of 64 years were operated by ISR using
silver-coated Dacron during the study period without operative death. The 30-day mortality was 22% and
the in-hospital mortality rate was 39%. Indeed, during hospitalisation, a duodenal leak was observed in
four patients including three who died. Four others patients died due to multi-system organ failure.
Median follow-up was 16 months (range 1e66). The survival rate at 12 months was 55%. One duodenal
leak was observed leading to death. The reinfection-free survival and the secondary patency rates at 12
months were 60% and 89%, respectively.
Conclusion: In-situ revascularisation with silver-coated Dacron provides acceptable results in terms of
mortality. This treatment may be useful for simple vascular reconstruction and allow greater attention to
bowel repair that is a determinant in short- and mid-term survival.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Secondary aorto-enteric ﬁstulae (SAEF) are observed after aortic
reconstruction in 1e2% of cases.1 They constitute one of the most
life-threatening complications in the ﬁeld of vascular surgery.
During the last decade, in-situ revascularisation (ISR) has been
preferred to extra-anatomic reconstruction (EAR), providing similar(D. Midy).
ciety for Vascular Surgery. Publisheresults in terms of survival and prevention of reinfection but with
better long-term patency and limb salvage.2 However, the ideal
conduit material for ISR remains a matter of debate. Recent reports
have shown that silver-coated Dacron (SCD) prostheses provide
similar results to fresh or cryopreserved arterial allografts in terms
of early mortality and mid-term survival.3,4
For frail patients, prosthetic grafts offer two major advantages
over femoral veins, that is, immediate availability and shorter
procedure time. The main drawback of prosthetic material is and by Elsevier Ltd. All rights reserved.
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ination. Moreover, we could think that this risk is particularly high
if the prosthesis is located in proximity to the site of bowel repair. In
this regard, duodenal leak has been identiﬁed as an independent
risk factor for mortality.5 The aim of this study was to evaluate the
short- and mid-term results of in-situ revascularisation using
a silver-coated Dacron prosthesis with duodenal repair for
management of SAEF in a homogeneous single-centre patient
population.
Material and Methods
Patients
This retrospective study is based on the medical records of
patients treated for a secondary aorto-enteric ﬁstula between
January 2006 and December 2010 in the vascular surgery depart-
ment of the Bordeaux University Hospital, France. Revascularisation
using a silver-coated Dacron was retrospectively analysed form
a database prospectively fulﬁlled collecting patient characteristics,
clinical ﬁndings, microbiological test results, radiological features
and operative outcomes. Aortic reconstructions using femoral
veins  cryopreserved allografts or ex situ revascularisation were
analysed frommedical charts, collecting patient characteristics and
operative outcomes.
Diagnosis
Computed tomography angiography (CTA) was performed to
conﬁrm diagnosis in all patients (Fig. 1). Diagnosis was based on
signs of aortic graft infection: pseudoaneurysm at the proximal
anastomosis, graft thrombosis, ﬂuid build-up around the graft and
the presence of gas bubbles and/or retroperitoneal abscess. Indi-
cations for ISR were determined based on patient’s general condi-
tion, clinical signs of infection and CTA ﬁndings. The decision to
perform ISR using an SCD prosthesis rather than femoral veins or
cryopreserved allografts was taken at a multidisciplinary meeting
based on concurrent disorders and technical considerations.
The patients who were stable at the time of presentation were
hospitalised and investigated in the surgical unit. All of them were
operated during the week following their admission. It was
considered urgent to operate the patients when they were hae-
modynamically unstable at the time of admission due to bleeding
or septical shock.Figure 1. Bowel contrast CT depicting a ﬁstula (black arrow) involving the right graft
limb and the third portion of the duodenum.Surgical technique
The operation was performed by a transperitoneal approach
under general anaesthesia. After control of the aorta proximally and
distally to the anastomosis and of the prosthetic limbs, the ﬁstula
was dissected and opened (Fig. 2). If vascular control was optimal,
the intestinal defect was repaired ﬁrst to reduce enteric contami-
nation. Bowel repair was achieved by direct suture (DS) for small
defects. For extensive lesions, duodenal reconstruction (DR) was
performed using the following technique. After resection of the
injured duodenum, generally the third and fourth segments, the
remaining duodenum was completely sutured and left in place on
the right side of the radix mesenterii. The jejunum was brought in
contact with the duodenum through a hole in the right mesocolon
and anastomosed side to side or side to end to the jejunum (Fig. 3)
in order to isolate intestinal repair site fromvascular reconstruction
site. In most cases, this technique was performed in association
with cholecystectomy with external drainage and with jejunos-
tomy for postoperative enteral nutrition. In the second phase of the
procedure, the infected aortic graft was excised either entirely or
partially if the infection seemed to be limited to one part of the
graft, particularly in cases involving well-encapsulated graft limbs.
The infected graft and tissues were sent for Gram stain, aerobic,
anaerobic and fungal culture. The surrounding tissue and tunnels
were excised followed by irrigation with serum and Rifampicin.
Vascular reconstruction was performed using an SCD graft (Inter
Gard Silver prosthesis; Inter Vascular, La Ciotat, France) pre-soaked
for at least 30 min in 600 mg Rifampicin powder solution (Merrell
Dow Pharmaceutical, Kansas City, MO, USA) diluted in 500 cc of
normal saline (2.4 mg ml1). The limbs of the graft were placed in
a new tunnel if dissection was not prevented by ﬁbrosis or in the
old tunnel if dissection was not possible. The new graft was thenFigure 2. intra-operative view showing the large duodenal defect (arrow head) and
the graft contaminated by the biliary secretion (arrow).
Figure 3. Duodenal reconstruction by 4th duodenal segment resection (arrow head)
and duodenal uncrossing with side to end anastomosis (arrow). An external biliary
drainage (asterix) is placed after cholecystectomy.
Table 1
Patients demographics: (%) or median (interquartile range). ASA: American Society
of Anaesthesiologists. SCD silver-coated Dacron. ISR in-situ reconstruction. EAR
extra-anatomic reconstruction.
Variables ISR with SCD ISR without SCD EAR without SCD
Male 18 (100) 6 (100) 2 (100)
Age 64 (61e68) 64 (59e73) 70 (68e72)
Comorbidities
Smoking 9 (50) 2 (33) 1 (50)
Coronaropathy 6 (33) 3 (50) 1 (50)
Dyslipidemia 7 (39) 2 (33) 0
Hypertension 10 (56) 4 (66) 2 (100)
Diabetes mellitus 1 (6) 2 (33) 0
ASA score
II 6 (33) 1 (17) 0
III 9 (50) 4 (66) 1 (50)
IV 3 (17) 1 (17) 1 (50)
Initial aortic reconstruction
Indication
Occlusive disease 11 (61) 4 (67) 2 (100)
Aortic Aneurysm 7 (39) 2 (33) 0
Conﬁguration
Aortobifemoral 13 (72) 4 (67) 2 (100)
Aortobiliac 4 (22) 2 (33) 0
Aortic tube 1 (6) 0 0
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closure of the retroperitoneum. Multiple suction drains were
placed in all cases. All patients received intravenous antibiotherapy
during the procedure.
Postoperative management
Following the procedure, all patients were transferred initially
to the critical care unit and then to the vascular department. Choice
and duration of antibiotherapy were determined by the infectious
diseases department based on the microbiological ﬁndings and
patient condition. In patients presenting complications or signs of
persistent infection, CTA was performed prior to discharge.
Follow-up
No patients were lost from follow-up. Follow-up included
examination in our department at 3, 6 and 12 months and yearly
thereafter. Examination included clinical and laboratory tests. CTA
was ordered only for patients with signs of recurrent infection, as
the presence of clinical signs of infection with fever and chills or
sepsis and biological markers with elevated C-reactive protein
(CRP) and white cell count when others causes of infection have
been excluded. The PET-CT was done only if some doubts persisted
after the CT scan and with high clinical suspicion of reinfection.
Deﬁnitions and end points
The 30-day mortality rate included deaths in the ﬁrst 30 post-
operative days. In-hospital mortality included all deaths occurring
during the procedure, and during the hospitalisation following the
procedure. Recurrent graft infection was deﬁned as a reinfection
with clinical and biological ﬁndings as explained before associated
with the presence of radiological signs of graft infection as deﬁned
in the manuscript, in patients who have been previously and
successfully operated for SAEF and discharged from the hospital.
The patients who died of sepsis or multiple organ failure (MOF)
were not considered as reinfected. Primary patency was deﬁned as
the period of uninterrupted graft patency after revascularisation.
Secondary patency was deﬁned as the period of graft patencyfollowing re-do for occlusion. The in-hospital mortality rate and
KaplaneMeier estimate of the survival rate were considered as
primary outcomes. KaplaneMeier estimates of the reinfection-free
survival rate and of the primary and secondary patency rates were
deﬁned as secondary outcomes.
Statistics
Statistical analysis was carried out using SAS 9.1 statistical
software. Descriptive statistics were used to show the distribution
of variables in the population. Values are expressed as median and
interquartile range for quantitative variables and as number and
percentage for qualitative variables. Survival rate, recurrent graft
infection-free survival rates and primary and secondary patency
rates were estimated with the use of the KaplaneMeier method.
Results
Study population and pre-operative ﬁndings
During the study period, 18 male patients with a median age of
64 years (interquartile range, 61e68) underwent ISR with SCD
prostheses for SAEF in our department. Patient characteristics are
described in Table 1. Median time from the initial reconstruction to
the diagnosis of the SAEF was 5.5 years (interquartile range, 5e9).
All patients were symptomatic at the time of presentation and
the majority had hyperthermia (Table 2). In addition to the CT scan
(Table 2), gastrointestinal endoscopy was performed in the eight
patients with gastrointestinal bleeding and conﬁrmed SAEF in two.
Surgical procedure
Five patients (28%) were operated within the 6 h following
admission to the hospital due to haemodynamic instability. Three
of them presented with haemorrhagic shock due to rectal bleeding
or haematemesis and the two remaining patients were septic. The
other 13 patients underwent elective surgery within 1 week after
admission. Total excision of the infected graft was achieved in 14
patients (78%). In the remaining four cases involving aortobife-
moral bypass grafts, limb encapsulation prevented total excision.
Vascular reconstruction consisted of aortoiliac bypass in nine cases
Table 2
Clinical presentation and pre-operative exams ﬁndings for the 18 patients treated by
ISR with SCD.
Number (%)
Clinical signs
Hyperthermia 9 (50)
Cellulitis 5 (28)
Groin 2 (11)
Calf (septic embolus) 2 (11)
Knee (arthritis) 1 (6)
Gastrointestinal bleeding 8 (44)
Maelena 2 (11)
Rectal bleeding 3 (17)
Haematemesis 3 (17)
Acute limb ischaemia 2 (11)
CT scan ﬁndings
Perigraft ﬂuid 17 (94)
Retroperitoneal abscess 5 (28)
Perigraft gas 14 (78)
Graft thrombosis 5 (28)
Proximal pseudoaneurysm 3 (17)
Pre-operative gastrointestinal endoscopy 8 (44)
Positive pre-operative bloodstream cultures 7 (39)
Table 3
Bacteriological ﬁndings for the 18 patients treated by ISR with SCD.
pre-operative
blood culture (%)
Postoperative tissue
and graft samples
culture (%)
Patients with
1 micro-organism cultured 7 (39) 12 (67)
2 micro-organisms cultured 0 3 (17)
>2 micro-organisms cultured 0 2 (11)
Sterile culture 6 (33) 1 (5)
Tests not realised 5 (28) 0
Organism cultured
Gram-negative
Escherichia coli 2 (11) 3 (17)
Pseudomonas aeruginosa 0 2 (11)
Bacteroides fragilis 0 2 (11)
Enterobacter cloacae 1 (5) 1 (5)
Proteus mirabillis 0 1 (5)
Gram-positive
Streptococcus alpha 2 (11) 3 (17)
Streptococcus anginosus 0 2 (11)
Methicillin-resistant
Staphylococcus aureus
1 (5) 2 (11)
Enterococcus faecalis 1 (5) 2 (11)
Corynebacterium 0 1 (11)
Fungus 5 (28)
Candida albicans 0 4 (22)
Candida kefyr 0 1 (5)
Anaerobes 0 1 (5)
J.C. Delva et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 417e424420(50%), aortobifemoral bypass in eight (44%) and aortic tube in one
(6%). Repair of the intestinal defect consisted of DS of the left colon
in one patient (5%), DS of the duodenum in seven patients (39%)
and duodenal reconstruction in 10 patients (55%). Median proce-
dure duration was 360 min (interquartile range, 240e435). No
operative death was recorded.
Bacteriology and antibiotherapy
Broad-spectrum intravenous antibiotherapy was administered
prior to surgery in 14 patients (78%) on the basis of blood cultures in
seven. It consisted in an association of tazobactam, piperacillin and
vancomycin for 8/14, tazobactam, piperacillin and gentamycin for
four and ceftazidim and amikacin for two. In the remaining four
cases, antibiotherapy was initiated during the procedure; it con-
sisted in an association of tazobactam, piperacillin and vancomycin.
Cultures of tissue and graft samples collected during the procedure
were positive in 17 cases (Table 3). Antibiotherapy was prescribed
for at least 6 weeks after the operation, with secondary adjustment
based on antibiogram ﬁndings in all positive cases.
In-hospital morbidity and mortality
The median duration of critical care was 9 days (interquartile
range, 6e16). Ten patients presented complications requiring at
least one re-operation (Table 4). During hospitalisation, four
patients (22%) required major amputation due to septic embolus in
one and acute limb ischaemia in the remaining three. During this
period, four patients presented a duodenal leak (three after a DR
and 1 after a DS). One of these four patients underwent gastro-
jejunal anastomosis but died from septic shock. The second
patient, with a small duodenal leak, was successfully treated by
external drainage under CT scan guidance and discharged at 44
days. The remaining two patients received only medical treatment
due to poor general condition and died from septic shock. Four
additional patients died from lethal MOF unrelated to bowel repair.
The 30-day mortality rate was 22% (4/18) and the in-hospital
mortality rate was 39% (7/18).
Follow-up
Median follow-upwas 16months (interquartile range,12.5e21).
During this period, graft infection recurred in four cases. In two ofthese recurrences, the patients presented with graft limb throm-
bosis at 10 and 12 months. In both of these cases, diagnosis was
conﬁrmed by CTA showing gas and ﬂuid around the graft. In one of
these patients (patient # 11), repeat duodenal reconstruction was
necessary due to duodenal leakage and associated with throm-
bectomy of one limb that was not replaced. In the other patient
(patient #2), excision of both the infected limb and leg amputation
was required after several failed revascularisation attempts. No
other case of graft thrombosis was observed. The KaplaneMeier
estimate of the primary and secondary graft patency at 12
months was 60.5 and 89%, respectively. The other two recurrent
graft infections were diagnosed at 5 and 13 months after lethal
septic rupture of the proximal anastomosis. Emergency laparotomy
conﬁrmed graft reinfection in both cases. One of these patients had
undergone successful medical treatment for a small duodenal leak
4 months earlier (patient #5). It was not possible to have some
samples in the two patients with septic rupture of aortawho died in
the follow-up. The other two patients with reinfection had
positive cultures with Escherichia coli. KaplaneMeier estimates of
reinfection-free survival (Fig. 4) and overall survival rates (Fig. 5) at
12 months were 60% and 55%, respectively.
Patients not treated by silver-coated Dacron
During the same period, eight male patients with a median age
of 68.5 years (interquartile range, 60e73) underwent a different
treatment: four reconstructions with femoral veins (two DR and
two DS), two reconstructions with a combination of femoral veins
and cryopreserved allografts (two DS) and two aortic ligations with
an axillo-bifemoral revascularisation (one DS and one DR). Patient
characteristics are listed in Table 1. The 30-day mortality rate and
the in-hospital mortality rate were 50% (1/2) for ex situ recon-
struction (one MOF at day 26) and 50% (3/6) for in-situ recon-
struction (one intra-operative death, two graft disruptions at day 4
and 14). Among the four patients alive at day 30, the patient with ex
situ reconstructionwas lost from follow-up at 3months, one died at
25 months from unknown cause and the remaining two are still
Table 4
Details of in-hospital and follow-up complications and mortality for the 18 patients treated by ISR with SCD. D:Day; M:month; GO: Graft occlusion; BGO: Below graft occlusion; MSOF: Multi-system organ failure.
In-hospital Follow-up
Patient Responsible
micro-organism
Type of
graft
Surgical complications Reintervention Cause of death Recurrent graft
infection
Graft
thrombosis
Reintervention Cause of death Last follow-up
1 Prevotella buccae AI Alive (M37)
2 Bacteroides fragilis AF Acute limb ischaemia:
BGO (D0)
Femoro-popliteal
bypass
Graft limb (M12) Graft limb
(M12)
Thrombectomy þ Bypass
Leg amputation þ excision
of infected graft limb (M12)
Alive (M18)
3 SARM AI Proximal
pseudoaneurysm
(M13)
Urgent laparotomy (M13) Rupture of proximal
pseudoaneurysm
(M13)
Dead
4 Candida albicans AI Duodenal leak (D28) Gastro-jejunal
anastomosis
Septic shock (D41) Dead
5 Proteus mirabillis AF Duodenal leak (D15) No reintervention:
external drainage
Proximal
pseudoaneurysm
(M5)
Urgent laparotomy (M5) Rupture of proximal
pseudoaneurysm
(M5)
Dead
6 Streptococcus anginosus AI Alive (M66)
7 AF Acute limb ischaemia:
BGO (D2)
Leg amputation MSOF (D4) Dead
8 Streptococcus alpha AI Acute limb ischaemia:
GO (D1)
Graft thrombectomy Alive (M16)
9 Candida albicans
Streptococcus alpha
AI Alive (M17)
10 Enterococcus faecalis
SARM
Pseudomonas aeruginosa
Bacteroides fragilis
AF Acute limb ischaemia:
BGO (D15)
Femoro-popliteal
bypass thrombectomy
Alive (M20)
11 Pseudomonas aeruginosa
Enterobacter cloacae
AI Graft limb
(M10)
Graft limb
(M10)
Thrombectomy þ new
duodeno-jejunal
anastomosis (M10)
Alive (M22)
12 E. coli AF Acute limb ischaemia:
GO (D0)
Acute limb ischaemia:
BGO (D7)
Graft thrombectomy
Leg amputation
Multi system organ
failure (D60)
Dead
13 Candida kefyr AF Alive (M16)
14 Candida albicans
Streptococcus alpha
Corynebacterium
AF Left colonic necrosis
(D15)
Left colectomy Multi system organ
failure (D26)
Dead
15 Enterobacter faecalis
Streptococcus anginosus
AI Duodenal leak (D7) Septic shock (D12) Dead
16 E. Coli Aortic
tube
Leg abscess after
initial septic
embolus (D9)
Leg amputation Alive (M5)
17 E. Coli AI Acute limb ischaemia:
GO (D1)
Graft thrombectomy Multi system organ
failure (D9)
Dead
18 Candida albicans AF Acute limb ischaemia:
BGO (D1)
Acute limb ischaemia:
BGO (D4)
Duodenal leak (D4)
Femoro-popliteal
bypass thrombectomy
Leg amputation
Septic shock (D38) Dead
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Figure 4. KaplaneMeier estimates of reinfection-free survival rate for the 18 patients treated by ISR with SCD.
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were patent during the study period.
Discussion
In this study, 18 patients underwent bowel repair and in-situ
revascularisation using silver-coated Dacron to treat SAEF. There
were seven in-hospital deaths (39%), due to duodenal leak in three
cases and the estimate of survival rate at 12 months reached 55%.
The estimate of recurrent graft infection-free survival at 12 months
was 60% and the estimates of primary and secondary patency rates
were 60.5% and 89%, respectively.
For many years, EAR has been the gold standard for the treat-
ment of infected aortic grafts, especially in association with SAEF.
Indeed, EAR provides acceptable rates of mortality and graft rein-
fection while avoiding challenging aortic reconstruction in a septicFigure 5. KaplaneMeier estimates of survival rateﬁeld.6,7 However, some authors have reported elevated mortality
rates due to rupture of the aortic stump after EAR8 and axillofe-
moral bypass has been associated with graft thrombosis and lower
limb amputation.9 Because of these disadvantages, several surgical
teams have proposed ISR to improve long-term results in cases
involving infected aortic grafts. The use of this alternative was
supported by the Oderrich10 et al., 2006 study with a 40-month
follow-up showing a statistically higher graft patency rate after
ISR than EAR with no difference in operative mortality and
reinfection rates. The secondary patency rate in the present study
was 89%.
Despite numerous reports in the literature, controversy remains
concerning the best conduit material for ISR. Comparison of data is
difﬁcult because most previous series describing management of
aortic graft infection have included patients with or without SAEF
and the use of a wide range of vascular substitutes.2,11e15 In casesfor the 18 patients treated by ISR with SCD.
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as Pseudomonas aeruginosa or methicillin-resistant Staphylococcus
aureus (MRSA), femoral veins and cryopreserved allografts have
been vaunted as the best alternative to reduce the risk of rein-
fection.11,15e17 In a meta-analysis in 2006, O’Connor et al.2 showed
that autogenous veins remained the best material to avoid rein-
fection, and also reported complications at site of graft harvesting.
Similarly Ali et al.15 observed wound complications in 34% of the
patients. Modrall et al.18,19 described two other circulatory
complications, that is, deep venous insufﬁciency in 15% and
requirement for fasciotomy to prevent compartment syndrome
after aorto-femoral reconstruction in 21%. Another dreaded
complication is graft disruption that was the cause of death in 4% of
patients in the Kieffer et al. series using allografts11 and in 5% of
patients in the Ali et al. series using femoral veins.15 It is interesting
to note that most rupture-related deaths in patients treated for
SAEF occurred early after the intervention. In our experience, 2/6
patients treated by ISR using femoral veins died at day 4 and 14
from graft disruption. In sharp contrast with these ﬁndings, no
patient in our study using SCD prostheses required reintervention
for major bleeding.
Other advantages of SCD prostheses include immediate avail-
ability, long-term durability and better protection against infec-
tion.13 Indeed, although it is generally thought that the use of
foreign material in an infected ﬁeld is risky, a recent study4
comparing fresh allografts and silver-coated grafts showed no
difference in terms of reinfection. In our series, reinfection-free
survival at 1 year was 60% and only four patients developed late
reinfection. This is in accordancewith Oderich et al.20 who reported
an even lower reinfection rate of 4% using Rifampicin-soaked graft.
The same authors concluded that prosthetic grafts should be used
in cases of limited graft infection.
Unlike previous studies describing implantation of femoral
veins, cryopreserved allografts, speciﬁc soaked or coated grafts for
aortic reconstruction,2,11e13,15 our study focusses on the use of
silver-coated grafts for ISR in a homogeneous population of patients
presenting SAEF. It should be noted that the underlying physiopa-
thology of SAEF and diffuse infection seems quite different. Indeed,
SAEF is caused by bowel erosion caused by the pulsatile movement
of the prosthesis. In this context, graft infection is usually conﬁned
to the zone in contact with the bowel lesion20 (Fig. 2). In our study
only ﬁve patients presented perigraft effusion involving the whole
retroperitoneal space. Because the extent of infection was limited,
we were able to perform partial graft resection in four patients,
thus avoiding the need for difﬁcult dissection to remove the heavily
encapsulated graft segments. Only one of the four patients who
underwent partial resection developed late reinfection. Other
authors have reported similar good results after partial graft
resection.5,21,22
Another argument in favour of the use of prosthetic grafts such
as SCD for management of SAEF involves reducing the complexity
and invasiveness of the procedure, especially in frail patients. The
in-hospital mortality rate of 39% in this study is equivalent to rates
reported by other series describing SAEF management.5,16 It should
be noted that most deaths in our series occurred during the initial
hospitalisation period (7/9) and that more than half were due to
MOF early after the procedure. The most likely explanation is
inﬂammatory response related to procedure duration and surgical
trauma. This ﬁnding underlines the need to reduce the duration
and invasiveness of the procedure, especially for the aortobifemoral
reconstructions. Graft infection associated with SAEF seems to be
often limited to the graft segment in direct contact with the bowel
lesion as reported by Oderich et al., who reported partial replace-
ment of the infected graft in 80% of their cases of SAEF due to
localised infection.20 Moreover, SAEF is associated with lower rateof reinfection as compared to primary graft infection, probably due
to lowest virulence of the graft infection that is often partial.10
Therefore, selective ISR using an SCD prosthesis is a feasible alter-
native to more invasive and time-consuming replacement with
autologous material. In this regard, it can be noted that the mean
procedure duration in the study of Ali et al.15 using femoral veins
was 560 min as compared to 360 min in our study using selective
prosthetic reconstruction. Regarding these considerations, a new
alternative to conventional open surgery has been recently
described and analysed. Kakkos et al. reported better mid-term
outcomes using an endovascular approach with reduced early
mortality and morbidity without any difference in recurrence of
infection.23 However, further trials are required to conﬁrm these
results and to ﬁnd the exact place of this treatment.
Another important factor for successful management of SAEF is
effective visceral repair. In a recent study, Batt et al.5 noted a higher
incidence of lethal graft reinfection after direct suture of the
duodenal defect even if complete graft resection was achieved. The
lack of correlation between recurrence of graft infection and
revascularisation technique underlines the importance of bowel
repair. Protecting the revascularisation is a major factor in avoiding
direct contamination and reducing the risk of reinfection in case of
intestinal leakage. In addition to omental wrapping of the pros-
thesis,20 other revascularisation protection techniques such as
complex duodenal reconstruction and uncrossing can be used.
Although all of our patients with postoperative duodenal leaks
ﬁnally died, we can assume that the incidence of leakage and
complications would have been higher if direct duodenal suture
had been routinely performed. Our experience conﬁrms the ﬁnd-
ings of Valentine et al.24 who reported severe digestive complica-
tions in 10/38 patients with fatal outcome in 90% of cases and
identiﬁed gastrointestinal complications as an independent
predictor for death. Although the latter investigators performed DS
of the duodenal defect in 26 of 30 cases, they underlined the crucial
importance of managing the intestinal defect. Based on these
ﬁndings and our experience, we recommend direct duodenal
suture for small lesions but prefer resection and duodeno-jejunal
anastomosis for larger ones.
The main drawback of this study is retrospective design. Other
limitations include small patient population and short follow-up.
Conclusion
In-situ revascularisation with silver-coated Dacron provides
acceptable results in terms of mortality. This study shows that SAEF
still poses a difﬁcult surgical challenge associated with high
mortality. The use of SCD grafts may be useful for simple vascular
reconstruction and allow greater attention to bowel repair that is
a major factor in short- and mid-term survival.
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